Literature DB >> 6252141

Cefotaxime concentrations in ascites.

L Moreau, H Durand, P Biclet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6252141     DOI： 10.1093/jac/6.suppl_a.121

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  9 in total

1.  Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis.

Authors:  B A Runyon; E A Akriviadis; F R Sattler; J Cohen
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

2.  Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?

Authors:  J T Noble; M Barza
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Citrate in oral rehydration therapy.

Authors: 
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

Review 4.  Spontaneous bacterial peritonitis.

Authors:  I R Crossley; R Williams
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

5.  Distribution of ceftazidime in ascitic fluid.

Authors:  G Benoni; E Arosio; M G Raimondi; E Apolloni; E Passarella; A Lechi; G P Velo
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

6.  The pharmacokinetics of new cephalosporins: significance in clinical practice.

Authors:  H C Neu
Journal:  Bull N Y Acad Med       Date:  1984-05

7.  Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics.

Authors:  Tai-An Chen; Gin-Ho Lo; Kwok-Hung Lai; Whey-Jen Lin
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

Review 8.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 9.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.